Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Predictions

buy
LexaGene Holdings Inc.

Start price
Target price
Perf. (%)
€0.92
11.02.21
€2.00
11.02.22
-52.92%
20.04.21

buy
Aphria Inc.

Start price
Target price
Perf. (%)
€20.95
10.02.21
€22.00
11.75%
11.02.21

Revenue growth >5% per year expected
EBIT growth >5% per year expected
Standard Investments for future growth
High dividend yield expected
buy
Genfit S.A.

Start price
Target price
Perf. (%)
€5.45
10.02.21
-
-23.78%
21.03.21

Risky Investment
buy
Dexcom Inc.

Start price
Target price
Perf. (%)
€82.24
09.02.21
€87.50
09.02.22
29.20%
12.08.21

Could be worthwhile Investment >10% per year
Future proof or reliable business model
Sustainability is important
Higher risks for its business
buy
Clinuvel Pharmaceuticals

Start price
Target price
Perf. (%)
€13.90
09.02.21
-
09.02.22
10.47%
10.02.22

Fair valuation
Dependend from few customers or products
buy
Heat Biologics Inc.

Start price
Target price
Perf. (%)
€11.10
09.02.21
-
09.02.22
-41.26%
07.03.21

Could be worthwhile Investment >10% per year
Capable Management
Good culture
Some uniques
buy
Fresenius SE & Co. KGaA

Start price
Target price
Perf. (%)
€34.83
08.02.21
€41.00
16.07.21
27.92%
16.07.21

Could be worthwhile Investment >10% per year
Fair valuation
High dividend yield expected
Small challenges to pay loans and raise capital
CRH Medical Corp

Start price
Target price
Perf. (%)
€3.22
08.02.21
€3.00
08.02.22
-0.62%
22.02.21

Good culture
Probably not worthwhile Investment
Little innovation
No uniques
buy
Formycon AG

Start price
Target price
Perf. (%)
€67.20
08.02.21
-
08.02.22
-19.79%
09.02.22

buy
Atossa Genetics Inc

Start price
Target price
Perf. (%)
€3.44
08.02.21
€5.00
08.02.22
-27.31%
22.02.21

Could be worthwhile Investment >10% per year
buy
Star Equity Holdings Inc.

Start price
Target price
Perf. (%)
€3.12
08.02.21
€5.00
08.02.22
14.10%
22.02.21

Could be worthwhile Investment >10% per year
buy
InVivo Therapeutics Holdings

Start price
Target price
Perf. (%)
€32.25
08.02.21
€50.00
08.02.22
6.98%
22.02.21

Could be worthwhile Investment >10% per year
buy
Nuwellis Inc.

Start price
Target price
Perf. (%)
€7.35
08.02.21
€9.00
08.02.22
-1.36%
22.02.21

Could be very worthwhile Investment >20% year
buy
Formycon AG

Start price
Target price
Perf. (%)
€67.40
07.02.21
€80.00
07.02.22
-20.03%
08.02.22

Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
High valuation
Low dividend yield expected
buy
Seelos Therapeutics Inc.

Start price
Target price
Perf. (%)
€2.88
07.02.21
€5.00
07.02.22
-66.49%
08.02.22

Could be worthwhile Investment >10% per year
Top 10 in its market
buy
Canopy Growth Corp

Start price
Target price
Perf. (%)
€36.00
07.02.21
-
07.02.22
-80.67%
08.02.22

Probably not worthwhile Investment
High risks for its business
Few uniques
buy
T2 Biosystems Inc.

Start price
Target price
Perf. (%)
€137.50
06.02.21
€150.00
06.02.22
-67.82%
12.08.21

Could be worthwhile Investment >10% per year
Future proof or reliable business model
High valuation
MaxCyte Inc

Start price
Target price
Perf. (%)
€10.00
06.02.21
€10.00
06.02.22
33.00%
12.08.21

Capable Management
Future proof or reliable business model
Higher risks for its business
Idexx Laboratories Inc.

Start price
Target price
Perf. (%)
€416.00
06.02.21
-
06.02.22
7.91%
25.05.21

EBIT growth >5% per year expected
Very low/no dividend yield expected
buy
T2 Biosystems Inc.

Start price
Target price
Perf. (%)
€137.50
06.02.21
-
06.02.22
-10.00%
19.02.21

Could be very worthwhile Investment >20% year
T2 Biosystems Inc.

Start price
Target price
Perf. (%)
€132.95
05.02.21
€100.00
-10.68%
21.02.21

Risky Investment
buy
Bayer AG

Start price
Target price
Perf. (%)
€56.11
05.02.21
€90.00
05.02.22
-5.54%
05.02.22

Could be very worthwhile Investment >20% year
Revenue growth > 30% per year expected
EBIT growth > 30% per year expected
Rising EBIT margin expected
buy
Johnson & Johnson

Start price
Target price
Perf. (%)
€138.90
05.02.21
-
31.12.21
0.09%
29.03.21

Future proof or reliable business model
Could be worthwhile Investment >10% per year
Fair valuation
Innovative
buy
Fate Therapeutics Inc.

Start price
Target price
Perf. (%)
€82.00
02.02.21
€85.00
01.02.24
-96.49%
20.12.23

Could be worthwhile Investment >10% per year
Future proof or reliable business model
Some uniques
Innovative
Fresenius SE & Co. KGaA

Start price
Target price
Perf. (%)
€33.80
02.02.21
€30.00
16.02.21
0.27%
02.02.21